RET and non-small cell lung carcinoma: Briefly, NSCLC or MTC patients who progressed after initial response to selpercatinib or pralsetinib revealed three emerging distinct resistance mutations, namely, G810R/S/C within the RET solvent front, which are associated with impaired binding of selpercatinib and pralsetinib to RET fusions.